Search Results for: Respiratory

2697 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
DLG2 and GRIN1 discs large MAGUK scaffold protein 2 glutamate ionotropic receptor NMDA type subunit 1
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Glutamic Acid
  • Atomoxetine
  • Pentobarbital
  • Secobarbital
  • Pethidine
  • Acamprosate
  • Gabapentin
  • Memantine
  • Orphenadrine
  • Phenobarbital
  • Prasterone
  • Dcka, 5,7-Dichlorokynurenic Acid
  • D-Serine
  • Cycloleucine
  • Milnacipran
  • CNS-5161
  • Acetylcysteine
  • Ketobemidone
  • Gavestinel
  • Agmatine
  • Ifenprodil
  • Magnesium acetate tetrahydrate
  • Magnesium carbonate
  • Fluciclovine (18F)
DLG3 and NLGN3 discs large MAGUK scaffold protein 3 neuroligin 3
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • NrCAM interactions
  • Activation of Ca-permeable Kainate Receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Non-syndromic X-linked mental retardation
DLG3 and NLGN2 discs large MAGUK scaffold protein 3 neuroligin 2
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • NrCAM interactions
  • Activation of Ca-permeable Kainate Receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Non-syndromic X-linked mental retardation
DLG3 and NLGN1 discs large MAGUK scaffold protein 3 neuroligin 1
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • NrCAM interactions
  • Activation of Ca-permeable Kainate Receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Non-syndromic X-linked mental retardation
DLG3 and GRIN1 discs large MAGUK scaffold protein 3 glutamate ionotropic receptor NMDA type subunit 1
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • NrCAM interactions
  • Activation of Ca-permeable Kainate Receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Glutamic Acid
  • Atomoxetine
  • Pentobarbital
  • Secobarbital
  • Pethidine
  • Acamprosate
  • Gabapentin
  • Memantine
  • Orphenadrine
  • Phenobarbital
  • Prasterone
  • Dcka, 5,7-Dichlorokynurenic Acid
  • D-Serine
  • Cycloleucine
  • Milnacipran
  • CNS-5161
  • Acetylcysteine
  • Ketobemidone
  • Gavestinel
  • Agmatine
  • Ifenprodil
  • Magnesium acetate tetrahydrate
  • Magnesium carbonate
  • Fluciclovine (18F)
  • Non-syndromic X-linked mental retardation
DLG4 and NLGN3 discs large MAGUK scaffold protein 4 neuroligin 3
  • Signaling by ERBB4
  • Trafficking of AMPA receptors
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • NrCAM interactions
  • Activation of Ca-permeable Kainate Receptor
  • RHO GTPases activate CIT
  • RAF/MAP kinase cascade
  • LGI-ADAM interactions
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Guanidine
  • Guanosine-5'-Monophosphate
DLG4 and NLGN2 discs large MAGUK scaffold protein 4 neuroligin 2
  • Signaling by ERBB4
  • Trafficking of AMPA receptors
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • NrCAM interactions
  • Activation of Ca-permeable Kainate Receptor
  • RHO GTPases activate CIT
  • RAF/MAP kinase cascade
  • LGI-ADAM interactions
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Guanidine
  • Guanosine-5'-Monophosphate
DLG4 and GRIN1 discs large MAGUK scaffold protein 4 glutamate ionotropic receptor NMDA type subunit 1
  • Signaling by ERBB4
  • Trafficking of AMPA receptors
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • NrCAM interactions
  • Activation of Ca-permeable Kainate Receptor
  • RHO GTPases activate CIT
  • RAF/MAP kinase cascade
  • LGI-ADAM interactions
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Guanidine
  • Guanosine-5'-Monophosphate
  • Glutamic Acid
  • Atomoxetine
  • Pentobarbital
  • Secobarbital
  • Pethidine
  • Acamprosate
  • Gabapentin
  • Memantine
  • Orphenadrine
  • Phenobarbital
  • Prasterone
  • Dcka, 5,7-Dichlorokynurenic Acid
  • D-Serine
  • Cycloleucine
  • Milnacipran
  • CNS-5161
  • Acetylcysteine
  • Ketobemidone
  • Gavestinel
  • Agmatine
  • Ifenprodil
  • Magnesium acetate tetrahydrate
  • Magnesium carbonate
  • Fluciclovine (18F)
DLG4 and NLGN1 discs large MAGUK scaffold protein 4 neuroligin 1
  • Signaling by ERBB4
  • Trafficking of AMPA receptors
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • NrCAM interactions
  • Activation of Ca-permeable Kainate Receptor
  • RHO GTPases activate CIT
  • RAF/MAP kinase cascade
  • LGI-ADAM interactions
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Guanidine
  • Guanosine-5'-Monophosphate
DLX2 and GRN distal-less homeobox 2 granulin precursor
  • Neutrophil degranulation
  • Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
DMBT1 and SFTPA1 deleted in malignant brain tumors 1 surfactant protein A1
  • Surfactant metabolism
  • Toll Like Receptor 4 (TLR4) Cascade
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Signal regulatory protein family interactions
  • Surfactant metabolism
  • Regulation of TLR by endogenous ligand
  • Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5)
  • Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4)
  • 2-(N-Morpholino)-Ethanesulfonic Acid
DMBT1 and SFTPD deleted in malignant brain tumors 1 surfactant protein D
  • Surfactant metabolism
  • Toll Like Receptor 4 (TLR4) Cascade
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Signal regulatory protein family interactions
  • Surfactant metabolism
  • Regulation of TLR by endogenous ligand
  • Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5)
  • Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4)
  • Beta-D-Glucose
DNM1 and GRIN1 dynamin 1 glutamate ionotropic receptor NMDA type subunit 1
  • Toll Like Receptor 4 (TLR4) Cascade
  • Retrograde neurotrophin signalling
  • Gap junction degradation
  • Formation of annular gap junctions
  • MHC class II antigen presentation
  • EPH-ephrin mediated repulsion of cells
  • Recycling pathway of L1
  • Clathrin-mediated endocytosis
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Glutamic Acid
  • Atomoxetine
  • Pentobarbital
  • Secobarbital
  • Pethidine
  • Acamprosate
  • Gabapentin
  • Memantine
  • Orphenadrine
  • Phenobarbital
  • Prasterone
  • Dcka, 5,7-Dichlorokynurenic Acid
  • D-Serine
  • Cycloleucine
  • Milnacipran
  • CNS-5161
  • Acetylcysteine
  • Ketobemidone
  • Gavestinel
  • Agmatine
  • Ifenprodil
  • Magnesium acetate tetrahydrate
  • Magnesium carbonate
  • Fluciclovine (18F)
DMPK and RAC1 DM1 protein kinase Rac family small GTPase 1
  • Ion homeostasis
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Nef and signal transduction
  • NRAGE signals death through JNK
  • Rho GTPase cycle
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • FCERI mediated MAPK activation
  • DSCAM interactions
  • CD28 dependent Vav1 pathway
  • EPHB-mediated forward signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • PCP/CE pathway
  • Sema4D mediated inhibition of cell attachment and migration
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • Activation of RAC1
  • Inactivation of CDC42 and RAC1
  • VEGFA-VEGFR2 Pathway
  • Signal transduction by L1
  • VEGFR2 mediated vascular permeability
  • RHO GTPases activate PKNs
  • RHO GTPases activate CIT
  • RHO GTPases activate CIT
  • RHO GTPases activate KTN1
  • RHO GTPases activate IQGAPs
  • RHO GTPases activate PAKs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate Formins
  • RHO GTPases Activate Formins
  • RHO GTPases Activate NADPH Oxidases
  • MAPK6/MAPK4 signaling
  • Neutrophil degranulation
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAP1 and RAC1
  • NTRK2 activates RAC1
  • Activated NTRK2 signals through CDK5
  • Activation of RAC1 downstream of NMDARs
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • WNT5:FZD7-mediated leishmania damping
  • Factors involved in megakaryocyte development and platelet production
  • 3-[1-(3-Aminopropyl)-1h-Indol-3-Yl]-4-(1-Methyl-1h-Indol-3-Yl)-1h-Pyrrole-2,5-Dione
  • Dextromethorphan
  • Azathioprine
  • Guanosine-5'-Diphosphate
  • Myotonic dystrophy (DM)
DYNC1H1 and ECSIT dynein cytoplasmic 1 heavy chain 1 ECSIT signaling integrator
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • MHC class II antigen presentation
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • Regulation of PLK1 Activity at G2/M Transition
  • HSP90 chaperone cycle for steroid hormone receptors (SHR)
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • RHO GTPases Activate Formins
  • Neutrophil degranulation
  • COPI-mediated anterograde transport
  • COPI-independent Golgi-to-ER retrograde traffic
  • Mitotic Prometaphase
  • AURKA Activation by TPX2
  • HCMV Early Events
  • Aggrephagy
  • Aggrephagy
  • EML4 and NUDC in mitotic spindle formation
  • MyD88:MAL(TIRAP) cascade initiated on plasma membrane
  • Complex I biogenesis
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88 cascade initiated on plasma membrane
  • Distal hereditary motor neuropathies (dHMN)
DNM2 and HCK dynamin 2 HCK proto-oncogene, Src family tyrosine kinase
  • Toll Like Receptor 4 (TLR4) Cascade
  • Retrograde neurotrophin signalling
  • Gap junction degradation
  • Formation of annular gap junctions
  • NOSTRIN mediated eNOS trafficking
  • MHC class II antigen presentation
  • Lysosome Vesicle Biogenesis
  • Golgi Associated Vesicle Biogenesis
  • Recycling pathway of L1
  • Clathrin-mediated endocytosis
  • NGF-stimulated transcription
  • Nef and signal transduction
  • FCGR activation
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FLT3 Signaling
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • Phosphonotyrosine
  • Quercetin
  • Bosutinib
  • Centronuclear myopathy
  • Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
DNMT1 and MECP2 DNA methyltransferase 1 methyl-CpG binding protein 2
  • PRC2 methylates histones and DNA
  • NoRC negatively regulates rRNA expression
  • SUMOylation of DNA methylation proteins
  • DNA methylation
  • Azacitidine
  • Procainamide
  • Flucytosine
  • Decitabine
  • Epigallocatechin Gallate
DOCK1 and RAC1 dedicator of cytokinesis 1 Rac family small GTPase 1
  • Regulation of actin dynamics for phagocytic cup formation
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • VEGFA-VEGFR2 Pathway
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Nef and signal transduction
  • NRAGE signals death through JNK
  • Rho GTPase cycle
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • FCERI mediated MAPK activation
  • DSCAM interactions
  • CD28 dependent Vav1 pathway
  • EPHB-mediated forward signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • PCP/CE pathway
  • Sema4D mediated inhibition of cell attachment and migration
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • Activation of RAC1
  • Inactivation of CDC42 and RAC1
  • VEGFA-VEGFR2 Pathway
  • Signal transduction by L1
  • VEGFR2 mediated vascular permeability
  • RHO GTPases activate PKNs
  • RHO GTPases activate CIT
  • RHO GTPases activate CIT
  • RHO GTPases activate KTN1
  • RHO GTPases activate IQGAPs
  • RHO GTPases activate PAKs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate Formins
  • RHO GTPases Activate Formins
  • RHO GTPases Activate NADPH Oxidases
  • MAPK6/MAPK4 signaling
  • Neutrophil degranulation
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAP1 and RAC1
  • NTRK2 activates RAC1
  • Activated NTRK2 signals through CDK5
  • Activation of RAC1 downstream of NMDARs
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • WNT5:FZD7-mediated leishmania damping
  • Factors involved in megakaryocyte development and platelet production
  • Dextromethorphan
  • Azathioprine
  • Guanosine-5'-Diphosphate
DOCK2 and RAC1 dedicator of cytokinesis 2 Rac family small GTPase 1
  • Nef and signal transduction
  • Neutrophil degranulation
  • Factors involved in megakaryocyte development and platelet production
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Nef and signal transduction
  • NRAGE signals death through JNK
  • Rho GTPase cycle
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • FCERI mediated MAPK activation
  • DSCAM interactions
  • CD28 dependent Vav1 pathway
  • EPHB-mediated forward signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • PCP/CE pathway
  • Sema4D mediated inhibition of cell attachment and migration
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • Activation of RAC1
  • Inactivation of CDC42 and RAC1
  • VEGFA-VEGFR2 Pathway
  • Signal transduction by L1
  • VEGFR2 mediated vascular permeability
  • RHO GTPases activate PKNs
  • RHO GTPases activate CIT
  • RHO GTPases activate CIT
  • RHO GTPases activate KTN1
  • RHO GTPases activate IQGAPs
  • RHO GTPases activate PAKs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate Formins
  • RHO GTPases Activate Formins
  • RHO GTPases Activate NADPH Oxidases
  • MAPK6/MAPK4 signaling
  • Neutrophil degranulation
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAP1 and RAC1
  • NTRK2 activates RAC1
  • Activated NTRK2 signals through CDK5
  • Activation of RAC1 downstream of NMDARs
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • WNT5:FZD7-mediated leishmania damping
  • Factors involved in megakaryocyte development and platelet production
  • Dextromethorphan
  • Azathioprine
  • Guanosine-5'-Diphosphate
DOCK2 and RAC2 dedicator of cytokinesis 2 Rac family small GTPase 2
  • Nef and signal transduction
  • Neutrophil degranulation
  • Factors involved in megakaryocyte development and platelet production
  • GPVI-mediated activation cascade
  • ROS and RNS production in phagocytes
  • PIP3 activates AKT signaling
  • Rho GTPase cycle
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • PCP/CE pathway
  • RHO GTPases Activate NADPH Oxidases
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Dextromethorphan
  • Leukocyte adhesion deficiency (LAD), including the following four diseases: Leukocyte adhesion deficiency (I); Leukocyte adhesion deficiency (II); Leukocyte adhesion deficiency (III); LAD with Rac2 deficiency

Page 46 out of 135 pages